Latest Commercialization News

First Graphene Limited has broadened its North American footprint by appointing SuperGrafeno as its distributor in Canada, targeting the country’s infrastructure sector with its innovative graphene-enhanced cement and concrete products.

Provaris Energy has successfully raised $1.325 million through an oversubscribed placement, aiming to advance its 2026 development milestones in hydrogen and carbon dioxide storage technologies.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

dorsaVi has formed a world-class Technical Advisory Board to accelerate its pioneering ‘Intelligence at the Ultra Edge’ strategy, integrating advanced memory and neuromorphic computing into robotics and healthcare devices.

Blue Star Helium has successfully commissioned its Pinon Canyon Plant in the US, commencing integrated helium production and spot-market sales. CEO Trent Spry is on-site, advancing optimisation and strategic partnerships.

Noronex Limited has received the first A$1.25 million tranche payment from Joint Era Mining following due diligence completion on the Witvlei Copper Project sale, boosting its cash reserves and advancing its strategic focus.

Nexalis Therapeutics has initiated its Phase 1 trial for IRX-616a, an inhaled cannabidiol treatment aimed at panic disorder, marking a significant step in developing rapid-onset anxiety therapies.

ClearVue Technologies has locked in a $3 million structured funding facility tied to its R&D tax credits, aiming to accelerate certification milestones and commercial deployment without diluting shareholders.

OD6 Metals has secured an exclusive option to acquire the Quinn Fluorspar Project in Nevada, boasting ultra high-grade deposits critical to US supply chains. The move complements its rare earth and copper assets, backed by a $3.4 million capital raise.

The Calmer Co. International Limited’s Fiji subsidiary has secured a FJ$548k non-repayable grant to expand ready-to-drink production and upgrade supply chain infrastructure, accelerating its growth without diluting shareholder equity.

Island Pharmaceuticals has entered a pivotal research agreement with USAMRIID and the Geneva Foundation to accelerate FDA approval of Galidesivir for Marburg Virus Disease, leveraging top-tier US biodefense expertise.

Rhythm Biosciences has inked a pivotal distribution agreement with UK-based Digistain Limited to introduce its geneType™ genetic test portfolio in Southeast Asia, starting with the Philippines. This marks Rhythm’s first commercial foothold in the region, setting the stage for broader expansion.